Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRG Promethean: Relugolix + SABR in Oligometastatic Prostate Cancer
NCT05053152Phase 2Active, not recruiting
- Sponsor
- NRG Oncology
- Start
- Apr 2022
- Primary completion
- Feb 2029
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 2
01
Overview
A Phase 2 trial of tissue-plasminogen activator in prostate cancer (PCa), sponsored by NRG Oncology. Started Apr 2022; status: active, not recruiting.
02
Drugs
tissue-plasminogen activator
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05053152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05053152.